John S Wachtel, MD
Obstetrics/Gynecology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wachtel’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G35219 · Current
Licensed to practise in California · since 1977 · expires 2028-10-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$11,143
Medicare paid this office $11,143 for 81 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (45+ min) | 36 | $5,089 | $141 |
| New patient visit (30+ min) | 13 | $1,172 | $90 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 14 | $798 | $57 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 12 | $570 | $48 |
Who their Medicare patients are
81 Original Medicare patients in 2024. Average age 65 · Under 65 33% · Women 100% · Also on Medicaid 38% · Health risk score 1.12. Above the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 43% · Depression 31% · Diabetes 21% · Coronary heart disease 17%.
The office billed $54,110, Medicare allowed $14,890 and paid $11,143; for 109 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 81 | 109 | 65 | 1.12 | $54,110 | $11,143 |
| 2023 | 58 | 75 | 66 | 0.91 | $41,156 | $6,097 |
| 2022 | 58 | 82 | 68 | 0.98 | $43,812 | $6,028 |
| 2021 | 54 | 77 | 69 | 0.88 | $47,397 | $5,326 |
| 2020 | 48 | 67 | 69 | 0.70 | $31,284 | $3,664 |
| 2019 | 58 | 78 | 64 | 0.95 | $14,613 | $4,048 |
| 2018 | 52 | 71 | 70 | 1.50 | $6,609 | $3,086 |
| 2017 | 38 | 50 | 71 | 0.85 | $7,365 | $2,582 |
| 2016 | 49 | 63 | 72 | 0.83 | $10,897 | $3,297 |
| 2015 | 50 | 65 | 72 | 0.68 | $9,965 | $3,411 |
| 2014 | 78 | 117 | 74 | 0.74 | $19,502 | $6,849 |
| 2013 | 58 | 94 | 75 | 0.81 | $14,473 | $5,363 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 19 | $912 | $48 |
2022: 2 services
| New patient visit (30+ min) | 15 | $1,264 | $84 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 21 | $985 | $47 |
2021: 3 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 23 | $1,094 | $48 |
| New patient visit (30+ min) | 11 | $1,072 | $97 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 11 | $600 | $55 |
2020: 2 services
| Short return visit (20+ min) | 18 | $1,212 | $58 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 18 | $861 | $48 |
2019: 3 services
| New patient visit (30+ min) | 15 | $917 | $61 |
| Short return visit (20+ min) | 14 | $575 | $41 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 13 | $499 | $38 |
2018: 2 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 22 | $670 | $30 |
| New patient visit (15+ min) | 12 | $526 | $44 |
2017: 2 services
| Short return visit (20+ min) | 14 | $754 | $54 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 13 | $513 | $39 |
2016: 2 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 36 | $1,645 | $46 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 12 | $672 | $56 |
2015: 2 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 32 | $1,464 | $46 |
| Short return visit (20+ min) | 16 | $1,299 | $68 |
2014: 3 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 46 | $2,082 | $45 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 24 | $1,323 | $55 |
| Short return visit (20+ min) | 11 | $891 | $69 |
2013: 3 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 39 | $1,781 | $46 |
| Short return visit (20+ min) | 14 | $1,307 | $65 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 17 | $969 | $57 |
Medicaid work
$1,913 in 2024
Medicaid paid $1,913 for 16 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| New patient visit (45+ min) | 16 | $1,913 |
| 2024 | 16 | 1 | 16 | $1,913 |
Drugs they prescribed that Part D paid
$25,192
Pharmacies billed $25,192 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 110) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
66 generic and 44 brand-name prescriptions · $25,192 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estring | 18 | $9,307 | $517 |
| Premarin | 18 | $6,845 | $380 |
| Estradiol | 43 | $4,870 | $113 |
Year by year
| 2024 | 110 | 43 | 0% (0) | 40% | $25,192 |
| 2023 | 113 | 36 | 0% (0) | 44% | $31,812 |
| 2022 | 118 | 35 | 0% (0) | 40% | $28,808 |
| 2021 | 122 | 34 | 0% (0) | 52% | $31,476 |
| 2020 | 134 | 36 | 0% (0) | 63% | $36,175 |
| 2019 | 125 | 39 | 0% (0) | 52% | $26,093 |
| 2018 | 111 | 31 | 0% (0) | 51% | $25,121 |
| 2017 | 150 | 30 | 0% (0) | 68% | $31,584 |
| 2016 | 121 | 22 | 0% (0) | 67% | $22,547 |
| 2015 | 117 | 26 | 0% (0) | 72% | $24,460 |
| 2014 | 111 | 23 | 0% (0) | 72% | $19,613 |
| 2013 | 130 | 24 | None | 79% | $19,229 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Estring | 20 | $11,189 | $559 |
| Premarin | 20 | $7,942 | $397 |
| Estradiol | 49 | $7,342 | $150 |
2022: 3 drugs
| Estring | 15 | $8,088 | $539 |
| Premarin | 16 | $7,302 | $456 |
| Estradiol | 55 | $7,079 | $129 |
2021: 3 drugs
| Premarin | 33 | $11,532 | $349 |
| Estring | 15 | $7,537 | $502 |
| Estradiol | 48 | $5,967 | $124 |
2020: 4 drugs
| Premarin | 59 | $21,296 | $361 |
| Estring | 13 | $6,288 | $484 |
| Estradiol | 18 | $2,591 | $144 |
| Progesterone | 12 | $867 | $72 |
2019: 3 drugs
| Premarin | 46 | $15,932 | $346 |
| Estradiol | 24 | $2,062 | $86 |
| Doxycycline Hyclate | 14 | $375 | $27 |
2018: 4 drugs
| Premarin | 37 | $9,127 | $247 |
| Yuvafem | 22 | $3,807 | $173 |
| Estradiol | 14 | $2,901 | $207 |
| Progesterone | 11 | $673 | $61 |
2017: 5 drugs
| Premarin | 63 | $14,596 | $232 |
| Vagifem | 18 | $5,968 | $332 |
| Estring | 11 | $4,328 | $393 |
| Progesterone | 26 | $1,212 | $47 |
| Estradiol | 11 | $661 | $60 |
2016: 4 drugs
| Premarin | 46 | $8,511 | $185 |
| Estring | 15 | $4,748 | $317 |
| Progesterone | 16 | $711 | $44 |
| Estradiol | 16 | $257 | $16 |
2015: 3 drugs
| Premarin | 43 | $12,002 | $279 |
| Estring | 15 | $4,020 | $268 |
| Estradiol | 23 | $266 | $12 |
2014: 4 drugs
| Premarin | 47 | $8,931 | $190 |
| Estring | 12 | $2,777 | $231 |
| Valacyclovir | 13 | $535 | $41 |
| Estradiol | 14 | $202 | $14 |
2013: 6 drugs
| Premarin | 50 | $8,422 | $168 |
| Vagifem | 17 | $3,844 | $226 |
| Estring | 13 | $2,695 | $207 |
| Elidel | 12 | $2,139 | $178 |
| Progesterone | 12 | $1,151 | $96 |
| Estradiol | 12 | $352 | $29 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1457315194
- Licence
- CA G35219California G35219: Current · expires 2028-10-31
- Trained
- University of California, San Diego School of Medicine, 1976
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X); Federal specialty code 207VG0400X (207VG0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-04-12
- NPI last updated
- 2024-04-26
- NPI record certified
- 2024-04-26
This is when the NPI record was last certified, not a medical board exam.